This post has been archived and contains information that may be out of date.
Action Needed:
Urge your U.S. senators and representatives to support bipartisan legislation that preserves program eligibility for certain 340B hospitals during the COVID-19 public health emergency.
To find your senators’ contact information:
www.senate.gov/senators/senators-contact.htm
To find your representatives’ contact information:
Timing:
Call or email your representatives and senators by July 2.
Background:
The COVID-19 pandemic has resulted in a reduction in inpatient hospital admissions of low-income Medicare and Medicaid patients. This reduction has negatively affected some 340B hospitals’ Medicare disproportionate share hospital adjustment percentages, which impacts their eligibility to continue to participate in the 340B drug discount program.
H.R. 3203, introduced by Reps. Doris Matsui (D-CA) and Chris Stewart (R-UT), and S. 773, introduced by Sens. John Thune (R-SD) and Debbie Stabenow (D-MI), would enable hospitals that were participating in or applied for the 340B drug discount program prior to the COVID-19 public health emergency to temporarily maintain eligibility for the program by waiving the required minimum proportion of low-income patients served for hospitals.
Contact your representatives and senators and urge them to support the bipartisan House and Senate bills that would protect 340B hospitals and the communities they serve.
Additionally, CHA encourages 340B hospitals facing removal from the 340B drug discount program to email their eligibility concerns regarding the impact of patient mix changes due to COVID-19 directly to the Health Resources & Service Administration Office of Pharmacy Affairs staff: Capt. James Morris at JMorris@hrsa.gov and Chantelle Britton at CBritton@hrsa.gov. Please share a copy of your correspondence with Nicole Hoffman, federal relations manager, at nhoffman@calhospital.org.